Work

PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem

Year: 2026

Type: review

Abstract: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high-risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.

Source: Cardiovascular Therapeutics

DOI: 10.1155/cdr/7328020

Authors: Amirhossein Sahebkar, Wael Almahmeed, Prashant Kesharwani, Tannaz Jamialahmadi

Institutions: Mashhad University of Medical Sciences, Chitkara University, Cleveland Clinic Abu Dhabi, Chandigarh University, Dr. Hari Singh Gour University

Language: English

Topic: Atrial Fibrillation Management and Outcomes

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,160